Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 15;15(8):5339-5346.
eCollection 2023.

Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients

Qing Zhu  1 , Jingwen Zhang  1 , Derong Xu  1 , Rui Zhao  1
Affiliations

Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients

Qing Zhu et al. Am J Transl Res. .

Abstract

Objective: To investigate the relationship between PD-L1, Ki-67 and the association between PD-L1, Ki-67, and clinicopathologic features and laboratory parameters in the peripheral blood of non-small cell lung cancer (NSCLC) patients.

Methods: The clinical records of 213 NSCLC patients were retrospectively reviewed. The patients were divided into high or low expression groups by cut-off values of Ki-67 and PD-L1. Correlation of PD-L1 and Ki-67 expression were analyzed by linear regression analysis. The data were tested by Mann-Whitney test. Relationship of PD-L1 and Ki-67 was tested by chi-square test.

Results: Linear regression analysis revealed a positive association between the expression of PD-L1 and Ki-67 (R2=0.26, P<0.001). The clinicopathologic features and laboratory parameters such as gender, smoking history, histological types, TNM stage, tumor size, ALB, and FIB were all significantly associated with PD-L1 and Ki-67 expression (all P<0.05).

Conclusions: The expression of PD-L1 and Ki-67 is related to some clinicopathologic features and inflammatory factors, which brings new sight for exploiting combination biomarkers and therapeutic strategies.

Keywords: Ki-67; Non-small cell lung cancer; PD-L1; inflammation; proliferation.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
PD-L1 and Ki-67 correlation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783–791. - PMC - PubMed
    1. Mao Y, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. Surg Oncol Clin N Am. 2016;25:439–445. - PubMed
    1. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009. - PubMed
    1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85:8. - PMC - PubMed
    1. Garcia-Fernandez C, Fornaguera C, Borros S. Nanomedicine in non-small cell lung cancer: from conventional treatments to immunotherapy. Cancers (Basel) 2020;12:1609. - PMC - PubMed

LinkOut - more resources